Understand the source comparison
Survodutide GLP-1/Glucagon Complete Guide 2026: Comparison
Survodutide 6.0mg GLP-1 + Glucagon 18.6% −2.02% −22% (MRI-PDFF) Dual metabolic pathway. Appetite suppression plus energy expenditure increase Tirzepatide 15mg GLP-1 + GIP 20.9% −2.58% −18% (MRI-PDFF) Highest weight loss magnitude in Phase 3 trials Semaglutide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide 6.0mg
- GLP-1 + Glucagon
- 18.6%
- −2.02%
- −22% (MRI-PDFF)
- Dual metabolic pathway. Appetite suppression plus energy expenditure increase
- Tirzepatide 15mg
- GLP-1 + GIP
- 20.9%
- −2.58%
- −18% (MRI-PDFF)
- Highest weight loss magnitude in Phase 3 trials
- Semaglutide 2.4mg
- GLP-1 only
- 14.9%
- −1.44%
- −14% (MRI-PDFF)
- FDA-approved, widely available, established safety profile
- Liraglutide 3.0mg
- 8.4%
- −1.06%
- −9% (MRI-PDFF)
- Daily dosing, lower cost, approved since 2014
- Tirzepatide produces the highest weight loss in head-to-head trials, but survodutide's glucagon activity offers advantages in hepatic fat metabolism and MASH treatment that GLP-1/GIP agonism doesn't replicate. For research focused on metabolic dysfunction beyond weight loss alone. Hepatic steatosis, insulin resistance, energy expenditure. Survodutide provides mechanistic differentiation that justifies its use despite tirzepatide's superior weight outcomes.